These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35582170)

  • 1. Effect of Cyclophosphamide and Glucocorticoid Therapy in IgA Nephropathy: A Single-Center Retrospective Analysis.
    Beck N; Walz G; Schneider J
    Kidney360; 2022 Mar; 3(3):506-515. PubMed ID: 35582170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
    Ma F; Yang X; Zhou M; Bai M; Zhao L; Li L; Dong R; Liu C; Li R; Sun S
    J Nephrol; 2020 Dec; 33(6):1241-1250. PubMed ID: 32447619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
    Bagchi S; Singh G; Yadav R; Kalaivani M; Mahajan S; Bhowmik D; Dinda A; Agarwal SK
    Ren Fail; 2016; 38(3):431-6. PubMed ID: 26837482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and outcome of IgA nephropathy in children from one single center experience.
    Mao Y; Zhou W; Zhou Z; Zhang C; Shen J; Yin L
    BMC Pediatr; 2023 Jul; 23(1):377. PubMed ID: 37495962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and pathological analysis of IgA nephropathy with acute kidney injury].
    Chen MG; Ye XH; Liang HY; Yang Q
    Zhonghua Er Ke Za Zhi; 2016 Aug; 54(8):610-3. PubMed ID: 27510875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy
.
    Ihm HS; Lee JY; Hwang HS; Kim YG; Moon JY; Lee SH; Jeong KH; Lee TW; Ihm CG
    Clin Nephrol; 2019 Sep; 92(3):131-140. PubMed ID: 31232271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
    Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
    J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hematuria on the kidney disease progression in IgA nephropathy patients with mild proteinuria and well-preserved renal function.
    Liu Y; Chen H; Wang H; Li Z; Li H; Wang F; Jia J; Li D; Yan T
    Int Immunopharmacol; 2023 Sep; 122():110635. PubMed ID: 37453157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
    Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
    J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.
    He WJ; Wang J; Liu N; Li GY; Zhu XW; Yao L; Liu LL
    J Nephrol; 2024 May; 37(4):933-940. PubMed ID: 38225440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R; Lofaro D; Camilla RR; Bellur S; Cattran D; Cook HT; Roberts IS; Peruzzi L; Amore A; Emma F; Fuiano L; Berg U; Topaloglu R; Bilginer Y; Gesualdo L; Polci R; Mizerska-Wasiak M; Caliskan Y; Lundberg S; Cancarini G; Geddes C; Wetzels J; Wiecek A; Durlik M; Cusinato S; Rollino C; Maggio M; Praga M; K Smerud H; Tesar V; Maixnerova D; Barratt J; Papalia T; Bonofiglio R; Mazzucco G; Giannakakis C; Soderberg M; Orhan D; Di Palma AM; Maldyk J; Ozluk Y; Sudelin B; Tardanico R; Kipgen D; Steenbergen E; Karkoszka H; Perkowska-Ptasinska A; Ferrario F; Gutierrez E; Honsova E
    Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.
    Jia Q; Ma F; Yang X; Li L; Liu C; Sun R; Li R; Sun S
    Clin Exp Nephrol; 2022 Mar; 26(3):257-265. PubMed ID: 34724588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.
    Chakera A; MacEwen C; Bellur SS; Chompuk LO; Lunn D; Roberts ISD
    J Nephrol; 2016 Jun; 29(3):367-375. PubMed ID: 26318019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
    Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
    Yang X; Ma F; Bai M; Wang Y; Jia Q; Dong R; Liu C; Sun S
    Ren Fail; 2021 Aug; 43(1):1180-1187. PubMed ID: 34376108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of an IgA nephropathy cohort: outcomes and risk factors.
    Gadola L; Cabrera MJ; Garau M; Coitiño R; Aunchayna MH; Noboa O; Alvarez MA; Balardini S; Desiderio G; Dibello N; Ferreiro A; Giró S; Luzardo L; Maino A; Orihuela L; Ottati MG; Urrestarazú A
    Ren Fail; 2023 Dec; 45(1):2152694. PubMed ID: 36688795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy.
    Oshima S; Kawamura O
    Clin Exp Nephrol; 2008 Aug; 12(4):264-269. PubMed ID: 18324350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.